Rigel Pharmaceuticals, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

NET INCOME (LOSS) PER SHARE (Tables)

NET INCOME (LOSS) PER SHARE (Tables)

3 Months Ended

Mar. 31, 2022

Schedule of computation of basic and diluted earnings per share

The following table sets forth the computation of basic and diluted earnings per share (in thousands except per share amounts):


	Three Months Ended March 31,
	2022		2021
EPS Numerator:
Net income (loss)	$	(27,445)	$	39,500
EPS Denominator—Basic and Diluted:
Weighted-average common shares outstanding		171,774		169,800
EPS Denominator—Diluted:
Weighted-average common shares outstanding		171,774		169,800
Dilutive effect of stock options, restricted stock units and shares under Purchase Plan		—		6,269
Weighted-average shares outstanding and common stock equivalents		171,774		176,069

Net income (loss) per share
Basic	$	(0.16)	$	0.23
Diluted	$	(0.16)	$	0.22

Schedule of antidilutive securities

The potential shares of common stock that were excluded from the computation of diluted net income (loss) per share for the periods presented because including them would have been antidilutive are as follows (in thousands):


	Three Months Ended March 31,
	2022		2021
Outstanding stock options		32,639		8,183
Restricted stock units		1,206		2
Purchase Plan		312		—
Total		34,157		8,185